Beviprex Inhaler (9 mcg+4.8 mcg)/puff

Beviprex Inhaler (9 mcg+4.8 mcg)/puff Uses, Dosage, Side Effects, Food Interaction and all others data.

Each puff delivers- Through the actuator: Glycopyrronium Bromide EP 9 mcg and Formoterol Fumarate EP 4.8 mcg & Through the valve: Glycopyrronium Bromide EP 10.35 mcg and Formoterol Fumarate EP 5.52 mcg.

Beviprex Inhaler (9 mcg+4.8 mcg)/puff
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Beviprex Inhaler (9 mcg+4.8 mcg)/puff
Generic	Glycopyrronium Bromide + Formoterol Fumarate
Weight	(9 mcg+4.8 mcg)/puff
Type	Inhaler
Therapeutic Class
Manufacturer	Square Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

It is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Dosage

Beviprex Inhaler (9 mcg+4.8 mcg)/puff dosage

Adults: Should be administered as 2 puffs twice daily, in the morning and in the evening.Use in patients with severe renal impairment should be considered if the potential benefit of the treatment outweighs the risk.

Side Effects

The most common adverse reactions include cough and urinary tract infection. Possible side efects are sudden breathing problems, headache, tremor, nervousness, rash, swelling of the face, mouth and tongue, hives, increase blood pressure, chest pain, irregular heartbeat, muscle spasm, muscle weakness, eye pain or discomfort and urinary retention.

Precaution

This combination should not be used with an additional medicine containing a LABA because of risk of overdose. Not indicated for the relief of acute bronchospasm Do not initiate in acutely deteriorating COPD or to treat acute symptoms If paradoxical bronchospasm occurs, discontinue this combination and institute alternative therapy Use with caution in patients with cardiovascular disorders Use with patients with convulsive disorders, thyrotoxicosis, diabetes mellitus and ketoacidosis. Be alert to hypokalemia and hyperglycemia Worsening of narrow angle glaucoma may occur. Use with caution with patients with narrow-angle glaucoma Worsening of urinary retention may occur. Use with caution with patients with prostatic hyperplasia or bladder-neck obstruction

Interaction

Other adrenergic drugs may potentiate efect. Use with caution. Xanthine derivatives, steroids, diuretics or non-potassium sparing diuretics may potentiate hypokalemia or EDG changes. Use with caution. Diuretics: Use with caution. Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate efect of formoterol fumarate on cardiovascular system. Beta-Blockers: Use with caution and only when medically necessary. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administrations of this combination with other anticholinergic-containing drugs.

Pregnancy & Breastfeeding use

There are no data on the use of this preparation in pregnant women.

Contraindication

All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication. This preparation is also contraindicated in patients with hypersensitivity to glycopyrronium bromide, formoterol fumarate or to any component of the product.

Storage Condition

Do not store above 30°C. Do not expose to temperatures higher than 50°C. Do not pierce the pressurized container. Keep out of the reach of the children.